Shaily Engineering Plastics announced robust financial results for Q3 and 9M FY26. Consolidated Revenues grew by 27% (Q3) and 32% (9M). The key driver was the Healthcare segment, which surged 139% in Q3. The company also announced the appointment of Mr. Joe Kam as COO (Healthcare) and strategic capital expenditure for a new facility in Abu Dhabi to capitalize on the GLP-1 opportunity.
Q3 & 9M FY26 Financial Highlights (Consolidated)
Shaily Engineering Plastics reported significant top-line growth in the quarter ending December 2025. Consolidated Revenues for Q3 FY26 reached Rs. 250.5 Cr., a 27% increase YoY. For the nine-month period (9MFY26), Revenue stood at Rs. 753.8 Cr., marking a 32% growth. Profit After Tax (PAT) saw substantial expansion, rising 48% to Rs. 37.4 Cr. in Q3 and growing 101% to Rs. 165.7 Cr. over 9M.
Margin expansion was notable across the board. The Consolidated EBITDA Margin improved by 310 bps to 26.5% in Q3 FY26, while the 9M EBITDA Margin increased by 720 bps to 29.0%. Cash PAT for 9MFY26 grew 73% to Rs. 165.7 Cr.
Segmental Performance Drivers
The Healthcare segment was the primary growth engine for the company during Q3 FY26, showcasing a massive 139% revenue increase to Rs. 104.3 Cr. The 9M FY26 Healthcare revenue grew by an impressive 158% to Rs. 280.0 Cr. Conversely, the Consumer segment experienced a marginal decline of 13% in Q3.
Operational efficiency improved, with Machine Utilization across plants increasing by 250 bps to 47.1% in Q3 FY26. Domestic vs. Export revenue contribution shifted slightly, with exports rising from 20.6% in Q3 FY25 to 28.7% in Q3 FY26.
Key Business & Operational Updates
The company announced the appointment of Mr. Joe Kam as the new Chief Operating Officer (Healthcare), effective March 1, 2026, bringing over two decades of international experience in highly-regulated industries.
In the Healthcare business segment, Shaily onboarded 2 new customers in the fast-growing GLP-1 segment and signed 2 new contracts globally for pen injectors. Furthermore, the company is setting up a new facility in Abu Dhabi for manufacturing Medical Devices, with an estimated investment of AED 130–150 million and a capacity of approximately 75 million pen injectors p.a., targeted for operational status in Q4 FY28.
Capital Efficiency Metrics
The efficient use of capital significantly strengthened between March 2025 and December 2025 (consolidated). Return on Capital Employed (RoCE) rose by 1,400 bps to 38.4%, and Return on Equity (RoE) improved by 1,060 bps to 29.1%. The Total Debt/Equity ratio favorably decreased from 0.4 to 0.3 over the same period.
Source: BSE
